Skip to main content

Third Wave Stock Price Drops 7.8 Percent On News of Stratagene Suit

NEW YORK, May 12 (GenomeWeb News) - The share price of Third Wave Technologies has fallen 7.8 percent, or $.31, as investors reacted warily to the news that the company is being sued by Stratagene for alleged infringement of two of that company's copyrights.

 

Stratagene said Third Wave's Invader technology infringed on two of the four patents behind its FullVelocity line of Q-PCR products mid-day on May 9. Third Wave's stock price stood at $4.26 when the market closed May 9, and has dropped to $3.95 in mid-after noon trading today.

 

Third Wave sued Stratagene in September, claiming that FullVelocity patents infringed on its Invader patents. That suit is ongoing.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.